Sell-side analysts are offering a consensus “Buy” rating on shares of Inuvo, Inc. (:INUV). Using the following ratings scale: 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell and 5.0 Strong Sell, analysts have an average recommendation of 1.70. Based on a recent trade, the shares are hovering around $0.81 which, according to analysts, yield significant upside potential to the $2.72 consensus target price.
Inuvo, Inc. (:INUV) shares typically trade an average volume of 76.97 and institutions hold 30.20% of the total shares.
We see here that the stock is -5.41% away from the 20-Day Simple Moving Average. Their 50-Day Simple Moving Average is a difference of -12.24% from current levels. Further back, their 200-Day Simple Moving Average is -28.24% difference from today’s price. Currently, the stock is -34.68% from its 50-Day High and 15.40% from the 50-day low.
Inuvo, Inc. (:INUV)‘s stock has performed at -53.29%. Breaking that down further, it has performed -3.70% for the week, -10.34% for the month, -20.41% over the last quarter, -32.17% for the past half-year and -39.53% for this last year.
Onconova Therapeutics, Inc. (NASDAQ:ONTX) shares have been labeled a top pick by Beta Research as it meets the A+ criteria outlined by the firm. The stock boasts a consensus analyst “Buy” rating with the consensus recommendation standing at 2.00. This is according to all covering research brokerage firms taken into consideration by First Call. The consensus price target of $6.75 also implies significant upside from the current price of $1.64.
Onconova Therapeutics, Inc. (NASDAQ:ONTX)’s shares may have a significant upside to the consensus target of 6.75, but how has it been performing relative to the market? The stock’s price is 1.64 and their relative strength index (RSI) stands at 35.59. RSI is a technical oscillator that shows price strength by comparing upward and downward movements. It indicates oversold and overbought price levels for a stock.
Onconova Therapeutics, Inc. (NASDAQ:ONTX) shares are moving 3.80% trading at $1.64 today.